UK markets close in 6 hours 37 minutes
  • FTSE 100

    7,086.19
    +12.13 (+0.17%)
     
  • FTSE 250

    22,643.99
    -15.43 (-0.07%)
     
  • AIM

    1,231.34
    +0.25 (+0.02%)
     
  • GBP/EUR

    1.1710
    +0.0008 (+0.07%)
     
  • GBP/USD

    1.3977
    +0.0013 (+0.10%)
     
  • BTC-GBP

    23,730.71
    -718.38 (-2.94%)
     
  • CMC Crypto 200

    802.03
    -8.16 (-1.01%)
     
  • S&P 500

    4,241.84
    -4.60 (-0.11%)
     
  • DOW

    33,874.24
    -71.34 (-0.21%)
     
  • CRUDE OIL

    73.48
    +0.40 (+0.55%)
     
  • GOLD FUTURES

    1,782.10
    -1.30 (-0.07%)
     
  • NIKKEI 225

    28,875.23
    +0.34 (+0.00%)
     
  • HANG SENG

    28,882.46
    +65.39 (+0.23%)
     
  • DAX

    15,556.01
    +99.62 (+0.64%)
     
  • CAC 40

    6,602.78
    +51.71 (+0.79%)
     

World Age-Related Vision Dysfunction Epidemiology Forecast to 2030 - ResearchAndMarkets.com

·5-min read

The "Age-Related Vision Dysfunction - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Age-related Vision Dysfunction - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Age-related Vision Dysfunction epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Epidemiology Perspective

The Age-related Vision Dysfunction epidemiology division provides insights about historical and current Age-related Vision Dysfunction patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2020, the total prevalent case of Age-related Vision Dysfunction was 374,306,439 cases in the 7MM which are expected to grow during the study period, i.e., 2018-2030.

  • In the year 2020, the total prevalent case of Age-related Vision Dysfunction was 374,306,439 cases in the 7MM, and the US, in 2020, accounted for 159,952,427 cases (the highest number), which will probably rise during the study period, i.e., 2018-2030.

  • In the 7MM, the total diagnosed cases of Age-related Vision Dysfunction were 134,709,728 in the US, 140,935,350 in the EU5, and 38,601,941 cases in Japan in the year 2020.

  • In the 7MM, the total severity-specific prevalent cases of Age-related Vision Dysfunction were 244,080,761 for moderate to severe cases in the year 2020.

Country Wise- Age-related Vision Dysfunction Epidemiology

  • In the United States, the total number of prevalent cases of Age-related Vision Dysfunction was 159,952,427 cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.

  • In the year 2020, the total prevalent cases of Age-related Vision Dysfunction were 168,408,889 cases in EU-5 which are expected to grow during the study period, i.e., 2018-2030.

  • In Japan, the total number of prevalent cases of Age-related Vision Dysfunction was 45,945,123 cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population of Age-related Vision Dysfunction?

  • What are the key findings of the Age-related Vision Dysfunction epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018-2030)?

  • What would be the total number of patients with Age-related Vision Dysfunction across the 7MM during the study period (2018-2030)?

  • Among the EU5 countries, which country will have the highest number of patients during the study period (2018-2030)?

  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2018-2030)?

  • What are the various recent and upcoming events which are expected to improve the diagnosis of Age-related Vision Dysfunction?

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Executive Summary of Age-related Vision Dysfunction

4. Epidemiology Methodology

5. Disease Background and Overview

5.1. Introduction

5.2. Causes of Age-related Vision Dysfunction

5.2.1. Age-related Macular Degeneration (AMD)

5.2.2. Diabetic Retinopathy (DR)

5.2.3. Cataract

5.2.4. Glaucoma

5.2.5. Presbyopia

5.3. Signs and symptoms of Age-related Vision Dysfunction

5.4. Risk factors of Age-related Vision Dysfunction

5.5. Pathophysiology of Age-related Vision Dysfunction

6. Diagnosis of Age-related Vision Dysfunction

6.1. Patient History

6.2. Preliminary tests

6.3. Vision Acuity

6.4. Refraction

6.5. Fundus Fluorescein Angiography (FFA)

6.6. Indocyanine green angiography (ICG)

6.7. Amsler Grid Test

6.8. Visual Field Test

6.9. Tonometry Test

6.10. Ophthalmoscopy

6.11. Slit-lamp Examination

7. Diagnostic Guidelines

7.1. American Family Physician guidelines

7.2. The National Institute for Clinical Excellence (NICE) - Diagnostic Guidelines for AMD

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Epidemiology of Age-related vision dysfunction

8.3. Epidemiology Scenario: 7MM

8.4. Total Prevalent Cases of Age-related vision dysfunction

8.5. Total Diagnosed Cases of Age-related vision dysfunction

8.6. Severity-specific Cases of Age-related vision dysfunction

8.7. Total Treated Cases of Age-related vision dysfunction

9. The United States

9.1. Total Prevalent Cases of Age-related vision dysfunction

9.2. Total Diagnosed Cases of Age-related vision dysfunction

9.3. Severity-specific Cases of Age-related vision dysfunction

9.4. Total Treated Cases of Age-related vision dysfunction

10. EU-5

10.1. Germany

10.1.1. Total Prevalent Cases of Age-related vision dysfunction

10.1.2. Total Diagnosed Cases of Age-related vision dysfunction

10.1.3. Severity-specific Cases of Age-related vision dysfunction

10.1.4. Total Treated Cases of Age-related vision dysfunction

10.2. France

10.3. Italy

10.4. Spain

10.5. The United Kingdom

11. Japan

11.1. Total Prevalent Cases of Age-related vision dysfunction

11.2. Total Diagnosed Cases of Age-related vision dysfunction

11.3. Severity-specific Cases of Age-related vision dysfunction

11.4. Total Treated Cases of Age-related vision dysfunction

12. SWOT Analysis

13. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ei76a7

View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005499/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting